Skip to content
HowShorted

Tvardi Therapeutics, Inc. short interest in 2020

In 2020, Tvardi Therapeutics, Inc.'s disclosed short interest ran from 10.38% of shares outstanding on 15 Jan 2020 to 7.71% on 31 Dec 2020, a change of -2.67 percentage points. The year's high was 10.38% on 15 Jan 2020 and its low 7.02% on 30 Apr 2020, averaging 8.36% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.35 days on 31 Aug 2020. Full history: Tvardi Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Tvardi Therapeutics, Inc. in 2020

2020 in figures

Start of year
10.38% (15 Jan 2020)
End of year
7.71% (31 Dec 2020)
Change
-2.67 pp
High
10.38% (15 Jan 2020)
Low
7.02% (30 Apr 2020)
Average
8.36%
Highest days to cover
15.35 (31 Aug 2020)
SEC filings marked
8

Every report in 2020

Tvardi Therapeutics, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202010.38%8.13
31 Jan 20209.77%7.82
14 Feb 20209.24%11.88
28 Feb 20209.25%8.5110-K filed, results (8-K)
13 Mar 20209.10%8.19
31 Mar 20207.89%7.12
15 Apr 20207.48%9.38
30 Apr 20207.02%5.96
15 May 20207.99%6.2110-Q filed, results (8-K)
29 May 20207.83%8.45
15 Jun 20207.67%7.93
30 Jun 20208.58%6.91
15 Jul 20208.16%10.60
31 Jul 20207.90%13.60
14 Aug 20207.79%10.1310-Q filed, results (8-K)
31 Aug 20208.00%15.35
15 Sep 20208.20%11.80
30 Sep 20209.40%10.77
15 Oct 20209.65%12.21
30 Oct 20208.16%9.32
13 Nov 20207.69%10.3510-Q filed, results (8-K)
30 Nov 20207.73%12.68
15 Dec 20207.94%11.21
31 Dec 20207.71%9.48

See also: Tvardi Therapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.